United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Scott Gottlieb, former FDA commissioner, joins 'Squawk Box' to react to Pfizer's Covid-19 antiviral pill, which the company says was highly effective in clinical trials.

End of Covid pandemic in the U.S. is 'in sight': Dr. Scott Gottlieb

Booster doses as well as Pfizer's new Covid pills could be a powerful combo in the fight against Covid.

Pfizer CEO says Covid vaccines, boosters needed to break cycle of virus even with effective pills

Pfizer Inc (NYSE: PFE) is trading higher after the company announced its COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of a Phase 2/3 study. Pfizer said it will cease further enrollment into the study due to the overwhelming efficacy demonstrated in the results.

Why Pfizer Shares Are Surging Today

These are Insider's biggest healthcare stories for the week ending November 5.

What's ahead for COVID-19 treatments after Pfizer says its antiviral pill works

OSHA is requiring companies with 100 or more employees to ensure they are fully vaccinated or tested weekly for Covid, starting Jan. 4.

Pfizer board member Gottlieb says the Covid pandemic could be over in the U.S. by January

The drugmaker's oral COVID-19 pill knocked it out of the park in an important clinical trial.

Why Pfizer Gained $32 Billion in Market Capitalization Today

Shares of drug giant Pfizer surged more than 10% in early trading Friday after the company announced positive test results for an experimental pill it has developed to fight Covid-19.

Pfizer shares soar on positive test results for Covid pill

Pfizer Inc (NYSE:PFE)'s novel oral antiviral candidate Paxlovid has been shown to significantly reduce the risk of hospitalisation or death from COVID-19. In a phase 2/3 study of non-hospitalised adult patients with COVID-19 who were at high risk of progressing to severe illness, the interim analysis showed an 89% reduction in risk of COVID-19-related hospitalisation or death from any cause compared to placebo in patients treated within three days of symptom onset, Pfizer said in a statement.

Pfizer antiviral pill study shown to reduce risk of death from COVID-19 by 89%

The oral pill was found to reduce hospitalization or death from COVID-19 by 89%. Almost a year after Pfizer announced it had a working vaccine to fight COVID-19, the company has now announced that it has an oral treatment for those who become infected with the virus.

What to know about Pfizer's Covid-19 pill

Pfizer said its COVID-19 pill, when administered in conjunction with a widely used HIV drug, cut the risk of hospitalization or death by 89 percent.

Pfizer says COVID pill cuts risk of hospitalization, death by 89 percent

The company said its Covid-19 pill cut the risk of hospitalization or death by 89% in a trial of high-risk non-hospitalized adults, besting Merck's highly-touted Covid-19 pill molnupiravir.

Pfizer Stock Soars as Covid Antiviral Shows Stunning Efficacy

After Merck Co & Inc (NYSE: MRK), now Pfizer Inc (NYSE: PFE) has unveiled data for its COVID-19 oral antiviral candidate, Paxlovid. Paxlovid is an investigational SARS-CoV-2 protease inhibitor antiviral therapy.

Pfizer Touts Encouraging Data For Its COVID-19 Oral Antiviral, With 89% Reduction In Hospitalization, Death

Pfizer's new experimental COVID-19 antiviral pill cuts the risk of hospitalisation or death by 89%, the company has announced.

Pfizer's new COVID pill cuts hospitalisation or death by 89%, trial results indicate

Pfizer said its Covid-19 pill, used with an HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who've been exposed to the virus.

Pfizer says its Covid pill with HIV drug cuts the risk of hospitalization or death by 89%

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis showed an 89% reduc

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

"Our ability to stop living in fear is now within reach," Mikael Dolsten, Pfizer's chief scientific officer, told Insider.

'An extraordinary effect': Pfizer says its COVID-19 pill reduced the risk of hospitalization and death by 89% in high-risk patients

Merck

Vaxart

Only two of the pills are slated to be therapeutic.

3 COVID Pill Stocks That Might Be Game-Changers

Merck & Co. Inc. shares MRK, +2.10% slid 10% in premarket trading Friday, after Pfizer Inc. PFE, -1.31% said its antiviral treatment for COVID-19 was more effective in reducing the risk of hospitalization or death in high-risk adults than numbers reported recently by Merck for its antiviral. Pfizer said interim data from a Phase 2/3 trial of its oral antiviral treatment for COVID-19 reduced the risk of hospitalization or death by 89% in non-hospitalized high-risk adults with COVID.

Merck shares slide premarket as Pfizer soars on data from trial of rival COVID antiviral treatment

Pfizer Inc. shares PFE, -1.31% jumped 13% in premarket trade Friday, after the company said interim data from a Phase 2/3 trial of its oral antiviral treatment for COVID-19 reduced the risk of hospitalization or death by 89% in non-hospitalized high-risk adults with COVID. The company said the interim data set came from 1,219 adults who were enrolled in the trial by Sept.

Pfizer shares soar after data finds COVID antiviral reduced risk of death or hospitalization by 89% in high-risk adults

GlaxoSmithKline

VOXX International Corporation Class A

Kahn Brothers (Trades, Portfolio), the firm founded by the late Irving Kahn and his brothers Thomas Graham Kahn and Alan Kahn, disclosed this week that its top four buys during the third quarter were Pfizer Inc. ( PFE , Financial), VOXX International Corp. ( VOXX , Financial), BP PLC ( BP , Financial) and GlaxoSmithKline PLC ( GSK , Financial).

Kahn Brothers' Top 4 Buys in the 3rd Quarter

Adaptimmune Therapeutics

These two small-cap cancer companies would be a perfect fit for Pfizer.

2 Biotech Companies That Might Be on Pfizer's Radar Right Now

Here's the Single Most Important Detail in Pfizer's Q3 Update

Costco

Dow Inc

Lowe's

Nucor

Each of our large-cap picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy) and has a VGM Score of A. These are: NUE, PFE, DOW, COST and LOW.

Fed Chair Speaks in Cautious Tone Despite Tapering: 5 Picks

Abbott Labs

Alnylam Pharmaceuticals

Biogen

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.

The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter

Novavax

Walgreens

Here's why our trio of contributors likes Novavax, Pfizer, and Walgreens Boots Alliance.

News for Pfizer Stock (PFE)